Skip to main content
NCBI home page
Cureus logoLink to Cureus
. 2020 Mar 24;12(3):e7395. doi: 10.7759/cureus.7395

Intricate Interplay of Entwined Metabolic and Inflammatory Life-threatening Processes in Tumor Lysis Syndrome Complicating Prostate Cancer: A Systematic Review with a Single Institution Experience

Dawood Findakly 1, Jue Wang 2,✉
Editors: Alexander Muacevic, John R Adler
PMCID: PMC7096067  PMID: 32226700

Abstract

Tumor lysis syndrome (TLS) occurs in rapidly proliferating tumor cells, either spontaneously or after cytotoxic therapy. It has been well-documented in hematological diseases but is extremely rare in solid neoplasms, particularly in prostate cancer (PRCA). In the presence of risk factors, it can cause metabolic disturbances and be potentially fatal.

We searched PubMed, Medline, ScienceDirect, and Scopus for "tumor lysis syndrome" and "prostate cancer" and conducted a systematic review with a pooled analysis for the published literature and cases from our institution. Twenty-two TLS cases were identified (18 published in the literature and four cases from our institution). The patients' median age was 68 years (range 16-82), and most cases were prostate adenocarcinoma. The median prostate-specific antigen (PSA) was 374 (range 66.7-10,867). Ten cases (45.5%) had spontaneous TLS (STLS) while 12 cases (54.5%) were treatment-related (TTLS). All patients had elevated lactate dehydrogenase (LDH) with other biochemical variables, and all underwent aggressive supportive therapy. Eleven patients underwent hemodialysis, 12 patients received rasburicase, while three patients received allopurinol. The mortality rate was 75% among 12 cases of TTLS, and it was 30% of the 10 cases with STLS.

Among patients with PRCA, both TTLS and STLS linked to very high mortality. Early identification of TLS would substantially attain improved survival outcomes. Hence, physicians should consider TLS as a differential diagnosis when evaluating AKI and electrolyte abnormalities, particularly in patients with metastatic PRCA and high disease burden, even before the initiation of cytotoxic therapy.

Keywords: tumor lysis syndrome (tls), prostate cancer, metastasis, oncologic emergency, acute kidney injury (aki), cytokine storm, tumor necrosis factor-alpha, spontaneous tls (stls), treatment-related (ttls), systematic review

Introduction and background

Tumor lysis syndrome (TLS) is a major, life-threatening oncological emergency where hasty damage of tumor cells ends in a constellation of critical metabolic derangements. These constitute hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia, leading to an acute kidney injury (AKI), which further worsens TLS metabolic abnormalities and outcomes [1-5]. TLS divided into spontaneous TLS (STLS) and treatment-related (TTLS). Although TLS is widely known to occur in patients with rapidly proliferating chemosensitive hematologic diseases, it can seldom happen in solid tumors. Recent papers were published indicating prostate cancer (PRCA) as being one of the solid tumors that can exceptionally rarely be complicated by TLS [6-24]. This study's objective is to investigate the clinical characteristics, management, and outcomes of TLS, a rare oncologic emergency, in patients with PRCA.

Review

Aim of the study

This review aims to examine the available published information on the clinical characteristics, treatment, and outcomes of TLS in patients with prostate cancer.

Patients and methods

Literature Search Strategy

A systematic analysis through a comprehensive literature search was conducted and pooled with cases from our institution. We searched PubMed, Medline, ScienceDirect, and Scopus for "tumor lysis syndrome" and "prostate cancer." The identified list of cases and abstracts were reviewed and screened for any additional articles of interest from reference lists.

Data Extraction and Statistical Analysis

We extracted data on age at diagnosis, histological subtypes, prostate-specific antigen, Gleason score, diagnostic radiology, comorbid status, treatment, and outcomes were also recorded when available. Four cases from our institution were included in our analysis. We interpreted the pooled data and summarized it through descriptive statistics using central tendency and dispersion measures.

Results

We recognized 18 publications where TLS occurred in the setting of PRCA (14 case reports and four meeting abstracts). Out of the 18 cases of TLS, we identified 12 TTLS cases and six STLS cases. Furthermore, we identified four cases of STLS diagnosed in our institutional database. The final cohort was consistent with a total of 22 PRCA patients with TLS.

The demographics, clinicopathologic features, and survival outcomes of 22 cases of TLS in PRCA are summarized in Table 1. The mean age (± SD) was 63.5 (±14.5) years. The median prostate-specific antigen (PSA) was 374 (range 66.7-10,867 ng/mL). Most cases were prostate adenocarcinoma (except prostate rhabdomyosarcoma in one case, prostate small cell carcinoma (SCC) in two cases, and pathology type not documented in four cases). High-grade Gleason 8+ PRCA documented in 80% of cases with available data, including two cases of prostate SCC. All cases (100%) reported distant metastases. Of the cases with available data, 100% had bone metastasis and 52% had liver metastasis. Ten cases (45.5%) had STLS. In contrast, 12 TLS cases (54.5%) were associated with a variety of treatment regimens before developing TLS; out of these, six patients received chemotherapy (27.3%), three cases received hormonal treatment (13.6%), two received radiation therapy (9.1%), and one case developed TLS after treatment with methylprednisolone for pembrolizumab-induced acute liver injury (4.5%). All patients had elevated lactate dehydrogenase (LDH) with other biochemical variables such as uric acid, potassium, phosphorus, and creatinine. All patients received aggressive supportive therapy, 11 (50%) underwent hemodialysis, 12 (54.5%) received rasburicase, and three (13.6%) received allopurinol (Figure 1).

Table 1. Summary of available publications and our hospital data for characteristics of patients with TLS in PRCA.

PRCA: prostate cancer; TLS: tumor lysis syndrome; PSA: prostate-specific antigen; Mets: metastases locations; Ref: references; ND: no data; STLS: spontaneous TLS; SCC: small cell carcinoma; LN: lymph nodes; TURBT: transurethral resection of bladder tumor

Author Year Age Histology Gleason score PSA Mets Treatment preceding TLS Time to TLS (days) Rasburicase Other management Outcome Ref
Sorscher 2004 80 Adenocarcinoma 3+3 348 Bone Docetaxel, dexamethasone 1 No Furosemide Died [6]
Tanvetyanon and Choudhury 2004 77 Adenocarcinoma ND 10,867 Bone, liver Flutamide, goserelin 6 No Supportive therapy Died [7]
Wright et al. 2005 60 Adenocarcinoma 3+4 5520 Bone Paclitaxel 1 No Hemodialysis Died [8]
Lin et al. 2007 72 Adenocarcinoma ND 66.7 Bone, liver Flutamide, leuprolide, dexamethasone, medroxyprogesterone 21 No Hemodialysis, furosemide, allopurinol Died [9]
Hashem et al. 2010 73 Adenocarcinoma ND ND Bone STLS ND No Hemodialysis Died [10]
Zulqarnain et al. 2012 56 Prostate SCC ND 6.1 Bone, LN, liver, lungs Chemotherapy 2 Yes Exchange transfusion for methemoglobinemia Alive [11]
Kaplan et al. 2012 60 Adenocarcinoma 5+4 300 Bone Radiation therapy to shoulder 6 Yes Sodium bicarbonate Died [12]
Nguyen and Ticona 2014 72 Adenocarcinoma ND ND Bone, LN STLS ND Yes Supportive therapy Alive [13]
Watanabe and Tanaka 2014 16 Prostate rhabdomyosarcoma ND ND Bone, LN STLS ND Yes Supportive therapy Alive [14]
Mazzoni 2016 62 Adenocarcinoma ND ND Bone, LN, bladder Radiation, TURBT, leuprolide, bicalutamide ND Yes Hemodialysis, sodium bicarbonate Died [15]
Serling-Boyd et al. 2017 56 Adenocarcinoma 5+4 548 LN, liver STLS ND Yes Sodium bicarbonate, furosemide, allopurinol Died [16]
Ignaszewski and Kohlitz 2017 69 Adenocarcinoma ND ND Bone, liver STLS ND Yes Hemodialysis, sodium bicarbonate Died [17]
Bhardwaj and Varma 2017 67 ND ND 4500 Bone, LN, liver Docetaxel 3 No Supportive therapy Died [18]
Gongora et al. 2018 46 Adenocarcinoma 4+4 917 Bone, LN, liver, lungs Carboplatin, etoposide 5 Yes Supportive therapy Alive [19]
McGhee-Jez et al. 2018 49 Adenocarcinoma ND 24.9 Bone STLS ND No Hemodialysis, allopurinol, prednisone Alive [20]
Oshima et al. 2019 77 ND 5+4 >1000 Bone, LN, liver Cabazitaxel 3 Yes Hemodialysis, sodium bicarbonate Died [21]
Sharma and Lane 2019 59 ND ND 2.1 LN, liver, adrenal glands Enzalutamide 30 Yes Hemodialysis Died [22]
Mayer and Zarouk 2019 71 ND ND ND ND on metastatic sites Methylprednisolone for pembrolizumab-induced acute liver injury 3 Yes Hemodialysis Alive [23]
Case 1, Wang 2016 72 Adenocarcinoma 4+5 746 Bone, LN STLS ND No Supportive therapy Alive [24]
Case 2, Wang 2018 53 Adenocarcinoma 4+4 374 Bone, LN, lungs STLS ND No Hemodialysis Alive [24]
Case 3 2018 82 Adenocarcinoma ND ND Bone, LN, liver STLS ND No Supportive therapy Alive [24]
Case 4 2019 69 Prostate SCC ND ND Bone, LN, liver, lungs, brain, adrenal STLS ND Yes Hemodialysis Alive [24]
Open in a new tab

Figure 1. Incidence rates of treatment-related versus spontaneous TLS in PRCA patients.

Figure 1

Open in a new tab

TLS: tumor lysis syndrome; PRCA: prostate cancer.

The mortality rate was 75% among 12 cases of TTLS, with a median survival of 4.5 days (range 1-30) from diagnosis of TLS to death, and 30% in the 10 cases with STLS. There was no reported mortality in the four cases recognized and managed in our institution.

Discussion

In our cohort, several findings are noteworthy. First, the high mortality in TLS most often occurs in PRCA patients with advanced-stage metastatic disease, significant disease burden, high Gleason score, and aggressive histology. Second, TLS in PRCA, particularly TTLS, displays poorer prognosis when compared to hematologic malignancies [25-27]. Third, we recognized two patients with primary prostate SCC. Similar to SCC in other locations, prostatic SCC histology has been linked to TLS and is known for its aggressive biological behavior and rapid proliferation rate [28-29]. Molecular studies identified a germline breast cancer susceptibility 2 (BRCA2) gene mutation in both cases. BRCA-positive PRCA patients tend to have a higher Gleason score, higher PSA, higher grade of tumor proliferation, and higher rate of metastasis, predisposing them to an early-onset, aggressive, and potentially fatal disease as compared to patients with BRCA negative tumors [30-33]. 

Research in animal models proposed additional mechanisms that might explain the higher mortality of TLS. Studies in mice found disseminated microemboli from lysed tumor cells during the histopathological postmortem examination; these result in widespread tissue damage, multiorgan failure, and death [34-35]. Those findings closely mimic the human autopsy findings of disseminated tumor embolism leading to massive tissue organ necrosis and death [36-37]. Furthermore, concurrent disseminated intravascular coagulation was proposed as a probable mechanism that could synergistically lead to increased mortality in patients with TLS through common pathogenesis and pro-inflammatory cytokine-mediated processes [13-14]. Further, upon investigating this entity, cytokines, especially TNF-alfa (TNFα) and Interferon-gamma (IFNγ), are considered key mediators of what is known as a "cytokine storm," first described by Aikawa in 1996 [38]. The cytokine storm reported having a positive correlation with the tumor burden and was thought to play a vital role in the pathophysiology of TLS [39-41]. A cohort by Nakamura et al. found an elevated serum interleukin-6 (IL-6), IL-8, and IL-10 cytokine levels in all treatment-related TLS patients and reported a 100% survival rate after receiving continuous hemodiafiltration for cytokine removal [41].

We were able to identify four cases of TLS in PRCA patients managed in our 450+ bed hospital, two of which were in the last 24 months. Since our last publication on this matter, we continued to have improved outcomes through our continued efforts for early identification of TLS in patients with PRCA [24,27].

Limitations of the study

Due to the inherent nature of retrospective studies, we were not able to perform a comprehensive assessment of factors that may impact the prognosis of TLS in prostate cancer patients, including the performance status and comorbid conditions. Larger sample size would further contribute to the stratification of the risk of patients based on treatment type before TLS development. Despite the limitations, this systematic review presents the most updated real-world insight regarding the diagnosis and prognosis of TLS in patients with metastatic prostate cancer. Our study will contribute to the evolving understanding of TLS in solid neoplasms and have implications for future cancer treatment paradigms in the era of targeted therapy.

Conclusions

Our study underscores that TLS is a real oncologic emergency, especially among patients with advanced PRCA. A heightened state of readiness orchestrated with increased attention to improve early detection of electrolytes abnormalities is immensely important for early TLS recognition and prompt intervention in patients with newly diagnosed metastatic PRCA even before starting cancer therapy. Further research is needed to determine the true incidence and molecular markers for TLS in solid tumors, which could, therefore, aid in improving outcomes.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Footnotes

The authors have declared that no competing interests exist.

References

  • 1.Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Abu-Alfa AK, Younes A. Am J Kidney Dis. 2010;55:0. doi: 10.1053/j.ajkd.2009.10.056. [DOI] [PubMed] [Google Scholar]
  • 2.The tumor lysis syndrome. Howard SC, Jones DP, Pui CH. N Engl J Med. 2011;364:1844–1854. doi: 10.1056/NEJMra0904569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Darmon M, Vincent F, Camous L, et al. https://www.ncbi.nlm.nih.gov/pubmed/23772757. Br J Haematol. 2013;162:489–497. doi: 10.1111/bjh.12415. [DOI] [PubMed] [Google Scholar]
  • 4.Tumor lysis syndrome in solid tumors: an up to date review of the literature. Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Rare Tumors. 2014;6:68–76. doi: 10.4081/rt.2014.5389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Am J Med Sci. 2003;325:38–40. doi: 10.1097/00000441-200301000-00008. [DOI] [PubMed] [Google Scholar]
  • 6.Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer. Sorscher SM. Cancer Chemother Pharmacol. 2004;54:191–192. doi: 10.1007/s00280-004-0827-9. [DOI] [PubMed] [Google Scholar]
  • 7.Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. Tanvetyanon T, Choudhury AM. J Urol. 2004;171:1627. doi: 10.1097/01.ju.0000115884.21275.f4. [DOI] [PubMed] [Google Scholar]
  • 8.Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Wright JL, Lin DW, Dewan P, Montgomery RB. Int J Urol. 2005;12:1012–1013. doi: 10.1111/j.1442-2042.2005.01196.x. [DOI] [PubMed] [Google Scholar]
  • 9.Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. Lin CJ, Hsieh RK, Lim KH, Chen HH, Cheng YC, Wu CJ. South Med J. 2007;100:916–917. doi: 10.1097/SMJ.0b013e318137a665. [DOI] [PubMed] [Google Scholar]
  • 10.Spontaneous tumor lysis syndrome: a case report and review of literature. Hashem AAH, Dowod TAHM, Abdelmajeed MM. https://pjms.com.pk/issues/aprjun2010/abstract/CaseReport1.html Pak J Med Sci. 2010;458:463. [Google Scholar]
  • 11.Tumor lysis syndrome in small cell cancer of prostate. Zulqarnain S, Bradley T, Demitis S. https://doi.org/10.1378/chest.1388951 Chest. 2012;142:626. [Google Scholar]
  • 12.Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis. Kaplan MA, Kucukoner M, Alpagat G, Isikdogan A. Ann Saudi Med. 2012;32:306–308. doi: 10.5144/0256-4947.2012.306-308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Spontaneous tumor lysis syndrome - a previously unrecognized complication of untreated prostate cancer - and DIC as the initial presentation of metastatic prostate cancer. Nguyen R, Ticona L. https://www.shmabstracts.com/abstract/spontaneous-tumor-lysis-syndrome-a-previously-unrecognized-complication-of-untreated-prostate-cancer-and-dic-as-the-initial-presentation-of-metastatic-prostate-cancer/ J Hosp Med. 2014;9:542. [Google Scholar]
  • 14.Successful prevention of tumor lysis syndrome using recombinant urate oxidase in patient with metastasic and bulky prostate rhabdomyosarcoma. Watanabe A, Tanaka R. Case Rep Clin Med. 2014;3:18–22. [Google Scholar]
  • 15.Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer. Mazzoni S. Int Urol Nephrol. 2016;48:1837–1838. doi: 10.1007/s11255-016-1369-x. [DOI] [PubMed] [Google Scholar]
  • 16.Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer. Serling-Boyd N, Quandt Z, Allaudeen N. Mol Clin Oncol. 2017;6:589–592. doi: 10.3892/mco.2017.1186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect. Ignaszewski M, Kohlitz P. Am J Emerg Med. 2017;35:1384–1381. doi: 10.1016/j.ajem.2017.05.044. [DOI] [PubMed] [Google Scholar]
  • 18.Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel. Bhardwaj S, Varma S. https://www.ncbi.nlm.nih.gov/pubmed/29284359. J Oncol Pharm Pract. 2018;24:153–155. doi: 10.1177/1078155217694492. [DOI] [PubMed] [Google Scholar]
  • 19.Tumor lysis syndrome after platinum-based chemotherapy in castration-resistant prostate cancer with a brca2 mutation: a case report. Gongora ABL, Canedo FSNA, de Melo ALA, Bezerra ROF, Asprino PF, Camargo AA, Bastos DA. https://www.clinical-genitourinary-cancer.com/article/S1558-7673(18)30638-4/abstract. Clin Genitourin Cancer. 2018;17:61–64. doi: 10.1016/j.clgc.2018.09.001. [DOI] [PubMed] [Google Scholar]
  • 20.Spontaneous tumor lysis syndrome as presenting sign of metastatic prostate cancer. Mcghee-Jez A, Batra V, Sunder T, et al. Cureus. 2018;10:0. doi: 10.7759/cureus.3706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: a case report. Oshima M, Mayumi S, Yazaki K, et al. IJU Case Reports. 2019;2:179–182. doi: 10.1002/iju5.12070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tumor lysis syndrome from autolysis in prostate cancer. Sharma AV, Lane ML. https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A6546 ATS J. 2019;199:1. [Google Scholar]
  • 23.Steroid-induced tumor lysis syndrome in the setting of pembrolizumab use. Mayer C, Zarouk S. https://doi.org/10.1053/j.ajkd.2019.03.242 Am J Kidney Dis. 2019;73:705. [Google Scholar]
  • 24.Tumor lysis syndrome associated with prostate cancer: an under-recognized oncologic emergency. Wang J. https://symbiosisonlinepublishing.com/criticalcare-diagnostic-management/criticalcare-diagnostic-management02.php J Emerg Crit Care Diagn Manag. 2018;1:1–3. [Google Scholar]
  • 25.Prognostic factors in prostate cancer. Buhmeida A, Pyrhönen S, Laato M, et al. Diagn Pathol. 2006;1:4. doi: 10.1186/1746-1596-1-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tumour lysis syndrome in solid tumours. Gemici C. Clin Oncol. 2006;18:773–780. doi: 10.1016/j.clon.2006.09.005. [DOI] [PubMed] [Google Scholar]
  • 27.The clinical features, outcome and prognosis of spontaneous tumor lysis syndrome in solid tumor. Harmon J, Allen S, Stoyanova D, Ruvinov K, Cassaday J, Wang J. https://scienceforecastoa.com/Articles/JORF-V1-E2-1009.pdf J Oncol Res Forecast. 2018;1:1009. [Google Scholar]
  • 28.Tumor lysis syndrome in small cell carcinoma and other solid tumors. Kalemkerian GP, Darwish B, Varterasian ML. Am J Med. 1997;103:363–367. doi: 10.1016/s0002-9343(97)00153-8. [DOI] [PubMed] [Google Scholar]
  • 29.Small cell carcinoma of the prostate. Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA. Nat Rev Urol. 2014;11:213–219. doi: 10.1038/nrurol.2014.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.The relevance of BRCA genetics to prostate cancer pathogenesis and treatment. Sundararajan S, Ahmed A, Goodman OB Jr. https://www.ncbi.nlm.nih.gov/pubmed/22252577. Clin Adv Hematol Oncol. 2011;9:748–755. [PubMed] [Google Scholar]
  • 31.Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Mitra A, Fisher C, Foster CS, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361443/#!po=65.3846. Br J Cancer. 2008;98:502–507. doi: 10.1038/sj.bjc.6604132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Immunohistochemical expression of BRCA1 and lethal prostate cancer. Fiorentino M, Judson G, Penny K, et al. Cancer Res. 2010;70:3136–3139. doi: 10.1158/0008-5472.CAN-09-4100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Agalliu I, Gern R, Leanza S, Burk RD. Clin Cancer Res. 2009;15:1112–1120. doi: 10.1158/1078-0432.CCR-08-1822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Spontaneous acute tumor lysis syndrome in a DBA/1J mouse: a case report and review. Lovelace K, van Gessel Y, Asher LV, Vogel P. Review Toxicol Pathol. 2003;31:486–490. doi: 10.1080/01926230390224674. [DOI] [PubMed] [Google Scholar]
  • 35.Spontaneous acute tumor lysis syndrome as a cause of early deaths in short-term carcinogenicity studies using p53 +/- mice. Vogel P, Pletcher JM, Liang Y. Vet Pathol. 2010;47:719–724. doi: 10.1177/0300985810363484. [DOI] [PubMed] [Google Scholar]
  • 36.A case of spontaneous tumor lysis syndrome in malignant melanoma. Takeuchi N, Miyazawa S, Ohno Z, Yoshida S, Tsukamoto T, Fujiwara M. World J Oncol. 2016;7:40–44. doi: 10.14740/wjon970w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer. Ito T, Ohta T, Narumi M, Sakaki H, Seino M, Sudo T, Nagase S. Gynecol Oncol Rep. 2018;24:21–23. doi: 10.1016/j.gore.2018.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults [Article in Japanese] Aikawa N. https://www.ncbi.nlm.nih.gov/pubmed/8940690. Nihon Geka Gakkai Zasshi. 1996;97:771–777. [PubMed] [Google Scholar]
  • 39.Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy. Smith L, Venella K. Clin J Oncol Nurs. 2017;21:29–34. doi: 10.1188/17.CJON.S2.29-34. [DOI] [PubMed] [Google Scholar]
  • 40.Cytokine release syndrome. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. J Immunother Cancer. 2018;6:56–10. doi: 10.1186/s40425-018-0343-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF) Nakamura M, Oda S, Sadahiro T, Hirayama Y, Tateishi Y, Abe R, Hirasawa H. https://doi.org/10.1016/j.transci.2008.11.004. Case Reports Transfus Apher Sci. 2009;40:41–47. doi: 10.1016/j.transci.2008.11.004. [DOI] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES